Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 3
2008 1
2013 1
2014 1
2015 1
2016 3
2017 1
2018 6
2019 8
2020 4
2021 9
2022 12
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
CRISPR-Cas systems for diagnosing infectious diseases.
Kostyusheva A, Brezgin S, Babin Y, Vasilyeva I, Glebe D, Kostyushev D, Chulanov V. Kostyusheva A, et al. Among authors: chulanov v. Methods. 2022 Jul;203:431-446. doi: 10.1016/j.ymeth.2021.04.007. Epub 2021 Apr 9. Methods. 2022. PMID: 33839288 Free PMC article. Review.
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group. Wedemeyer H, et al. Among authors: chulanov v. N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429. Epub 2023 Jun 22. N Engl J Med. 2023. PMID: 37345876 Free article. Clinical Trial.
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Zur Wiesch JS, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. Wedemeyer H, et al. Among authors: chulanov v. Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13. Lancet Infect Dis. 2023. PMID: 36113537 Clinical Trial.
Biomimetic approaches for targeting tumor-promoting inflammation.
Parodi A, Kostyushev D, Brezgin S, Kostyusheva A, Borodina T, Akasov R, Frolova A, Chulanov V, Zamyatnin AA Jr. Parodi A, et al. Among authors: chulanov v. Semin Cancer Biol. 2022 Nov;86(Pt 2):555-567. doi: 10.1016/j.semcancer.2022.04.007. Epub 2022 Apr 25. Semin Cancer Biol. 2022. PMID: 35472397 Review.
Gene Editing by Extracellular Vesicles.
Kostyushev D, Kostyusheva A, Brezgin S, Smirnov V, Volchkova E, Lukashev A, Chulanov V. Kostyushev D, et al. Among authors: chulanov v. Int J Mol Sci. 2020 Oct 5;21(19):7362. doi: 10.3390/ijms21197362. Int J Mol Sci. 2020. PMID: 33028045 Free PMC article. Review.
53 results